Cited 0 time in
Association and Prognostic Implications of “No-Reflow Phenomenon” and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Omar, Mohamed | - |
| dc.contributor.author | Kang, Min Gyu | - |
| dc.contributor.author | Jung, Moon Ki | - |
| dc.contributor.author | Ahn, Jong-Hwa | - |
| dc.contributor.author | Koh, Jin-Sin | - |
| dc.contributor.author | Guevarra, Phil Iver | - |
| dc.contributor.author | Kim, Sang-Wook | - |
| dc.contributor.author | Tantry, Udaya S. | - |
| dc.contributor.author | Gurbel, Paul A. | - |
| dc.contributor.author | Hwang, Jin-Yong | - |
| dc.contributor.author | Jeong, Young-Hoon | - |
| dc.date.accessioned | 2025-10-28T02:30:18Z | - |
| dc.date.available | 2025-10-28T02:30:18Z | - |
| dc.date.issued | 2025-11 | - |
| dc.identifier.issn | 2772-3747 | - |
| dc.identifier.issn | 2772-3747 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/80338 | - |
| dc.description.abstract | Background: Following percutaneous coronary intervention (PCI), the “no-reflow phenomenon” is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI. Objectives: This study aimed to evaluate the association between thrombogenicity profiles and “no-reflow phenomenon” during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI). Methods: From a real-world registry, we prospectively enrolled patients with STEMI who underwent primary PCI (n = 334). Thrombolysis In Myocardial Infarction flow grade was assessed at final angiography, and the “no-reflow phenomenon” was defined as Thrombolysis In Myocardial Infarction flow between 0 and 2. Thrombogenicity profiles were assessed with thromboelastography (TEG) and conventional hemostatic measurements. Results: Thirty-seven patients (11.1%) showed no-reflow after primary PCI. High platelet-fibrin clot strength (P-FCS: ≥ 68 mm) measured by TEG was significantly associated with an increased risk of post-PCI “no-reflow phenomenon” (OR: 2.611; 95% CI: 1.220-5.584; P = 0.010). The risk stratification with “no-reflow phenomenon” and “high P-FCS phenotype” appeared to be additive to predict the risk of 3-year clinical event (log-rank P < 0.001 across the groups). Patients with both “no-reflow phenomenon” and high P-FCS had a higher risk of adverse clinical events compared with normal-reflow subjects with low P-FCS (adjusted HR: 6.654; 95% CI: 2.678-16.530; P < 0.001). Conclusions: This study demonstrated a close relationship between heightened thrombogenicity (assessed by TEG P-FCS) with “no-reflow phenomenon,” and their additive prognostic implications after primary PCI in STEMI patients. Effective control of clot strength may reduce the risk of “no-reflow phenomenon” and improve clinical outcomes in these patients. (Gyeongsang National University Hospital Registry [GNUH]; NCT04650529) | - |
| dc.format.extent | 15 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Elsevier | - |
| dc.title | Association and Prognostic Implications of “No-Reflow Phenomenon” and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.jacasi.2025.07.015 | - |
| dc.identifier.scopusid | 2-s2.0-105016827394 | - |
| dc.identifier.wosid | 001614130500013 | - |
| dc.identifier.bibliographicCitation | JACC: Asia, v.5, no.11, pp 1487 - 1501 | - |
| dc.citation.title | JACC: Asia | - |
| dc.citation.volume | 5 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 1487 | - |
| dc.citation.endPage | 1501 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | esci | - |
| dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
| dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
| dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
| dc.subject.keywordPlus | CLOPIDOGREL | - |
| dc.subject.keywordPlus | BIVALIRUDIN | - |
| dc.subject.keywordPlus | REACTIVITY | - |
| dc.subject.keywordPlus | ASSAY | - |
| dc.subject.keywordAuthor | acute myocardial infarction | - |
| dc.subject.keywordAuthor | cardiovascular event | - |
| dc.subject.keywordAuthor | clot strength | - |
| dc.subject.keywordAuthor | no-reflow phenomenon | - |
| dc.subject.keywordAuthor | percutaneous coronary intervention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
